# Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)

> **NCT02382913** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 315 (actual)

## Conditions studied

- Pertussis

## Interventions

- **BIOLOGICAL:** aP booster
- **BIOLOGICAL:** TdaP booster
- **BIOLOGICAL:** Licensed TdaP booster (Boostrix®)

## Key facts

- **NCT ID:** NCT02382913
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382913, "Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02382913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*